FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register […]
Richard J. Bleicher, MD, FACS, Chief of the Division of Breast Surgery and Clinical Director of the Breast Service Line at Fox Chase Cancer Center.
The AACR June L. Biedler Prize for Cancer Journalism is a program of the AACR to raise awareness of the critical role that the media…
Help The Skin Cancer Foundation purchase and customize a new RV to keep our Destination Healthy Skin program on the road.
Chelsey Schlechter, MPH, PhD, has been chosen as a Cancer Moonshot Scholar. She is one of eleven researchers from across the country who have been…
PURPOSEGuidelines recommend cardiovascular (CV) risk assessment and counseling for cancer survivors. This study evaluated the automated heart-health assessment (AH-HA) clinical decision support tool to promote…
A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.
Testing for inherited cancer risk has become more accessible, affordable and accurate. Fred Hutch clinicians and researchers explain why it can be important, how to…
Health Canada has approved cilta-cel for use in patients with relapsed/lenalidomide-refractory multiple myeloma following 1 to 3 prior lines of therapy.
A quasi-experimental study sought to compare the 2 blood specimen collection methods to determine if one performed better for patients with central venous access devices.
AbstractBackground. Despite the increasing integration of wearable technology in oncology, its application in the care of older adults, representing most p
